<span item_type="fundamental" item_id="13f90b42d149b261fc765d3813013b12" counter_id="ST/US/ATYR" env="prod"></span><span item_type="announcement" item_id="648614715167803393" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -0.1457.</p><p></p><h4>Cash and Investment Position</h4><p>Cash, cash equivalents, restricted cash, and available-for-sale investments were $68,318 thousand as of March 31, 2026, compared to $80,922 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span></p><h4>Operating Expenses</h4><p>Research and development expenses were $7,317 thousand for the first quarter of 2026, a decrease from $11,814 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>General and administrative expenses were $4,119 thousand for the first quarter of 2026, an increase from $3,959 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>Total operating expenses were $11,436 thousand for the first quarter of 2026, down from $15,773 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span></p><h4>Operational Metrics</h4><p>Loss from operations was - $11,436 thousand for the first quarter of 2026, an improvement from - $15,773 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>Total other income (expense), net, was $644 thousand for the first quarter of 2026, compared to $892 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>Consolidated net loss was - $10,792 thousand for the first quarter of 2026, an improvement from - $14,881 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>Net loss attributable to aTyr Pharma, Inc. was - $10,791 thousand for the first quarter of 2026, an improvement from - $14,880 thousand for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span></p><h4>Balance Sheet Highlights</h4><p>Total assets were $79,654 thousand as of March 31, 2026, compared to $93,003 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>Total stockholders’ equity was $57,741 thousand as of March 31, 2026, compared to $67,288 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span></p><h4>Outlook / Guidance</h4><p>aTyr Pharma, Inc. plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis, using Forced Vital Capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span>The company is also on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm"></span></p>

ATYR Pharma | 8-K: FY2026 Q1 Revenue: USD 0